S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
NASDAQ:ALT

Altimmune (ALT) Stock Price, News & Analysis

$6.89
-0.15 (-2.13%)
(As of 04/18/2024 ET)
Today's Range
$6.85
$7.25
50-Day Range
$7.04
$13.81
52-Week Range
$2.09
$14.84
Volume
3.21 million shs
Average Volume
5.53 million shs
Market Capitalization
$488.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Altimmune MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
117.7% Upside
$15.00 Price Target
Short Interest
Bearish
25.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of Altimmune in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.52) to ($1.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.15 out of 5 stars

Medical Sector

762nd out of 918 stocks

Biotechnology Industry

27th out of 42 stocks

ALT stock logo

About Altimmune Stock (NASDAQ:ALT)

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

ALT Stock Price History

ALT Stock News Headlines

Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Altimmune Inc. NASDAQ: ALT is a clinical-stage biotechnology company specializing in treating liver disease and obesity. Their lead drug, Pemvidutide, has garnered much attention as a GLP-1/glucagon dual agonist similar to the weight-loss treatments Mounjaro and Zepbound by  Eli Lilly and Co. NYSE: LLY.
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
7 Stocks That Will Drive the Weight Loss Drugs Market (ALT)
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
Altimmune, Inc. (ALT)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
The 3 Best Biotech Stocks to Buy in April 2024
Eli Lilly: Three Threats To Its Huge Rally
Q4 2023 Altimmune Inc Earnings Call
ALT Stock Earnings: Altimmune Beats EPS for Q4 2023
See More Headlines
Receive ALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
4/18/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ALT
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$20.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+117.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-88,450,000.00
Net Margins
-20,780.75%
Pretax Margin
-20,762.21%

Debt

Sales & Book Value

Annual Sales
$430,000.00
Book Value
$2.75 per share

Miscellaneous

Free Float
67,988,000
Market Cap
$488.43 million
Optionable
Optionable
Beta
0.05
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Vipin K. Garg Ph.D. (Age 66)
    President, CEO & Director
    Comp: $986.14k
  • Dr. Matthew Scott Harris AGAF (Age 71)
    FCAP, M.D., MS, Chief Medical Officer
    Comp: $681.81k
  • Mr. Raymond M. Jordt M.B.A. (Age 51)
    Chief Business Officer
    Comp: $578.85k
  • Mr. Richard I. Eisenstadt M.B.A. (Age 66)
    Chief Financial Officer
    Comp: $619.69k
  • Mr. Bertrand Georges Ph.D.
    Chief Technology Officer
  • Dr. M. Scot Roberts Ph.D. (Age 65)
    Chief Scientific Officer
    Comp: $599.25k
  • Mr. Tony Blandin B.S.
    Vice President of Quality & Compliance Management
  • Mr. Andrew Shutterly M.S.
    Corporate Controller

ALT Stock Analysis - Frequently Asked Questions

Should I buy or sell Altimmune stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALT shares.
View ALT analyst ratings
or view top-rated stocks.

What is Altimmune's stock price target for 2024?

3 Wall Street analysts have issued 1-year target prices for Altimmune's shares. Their ALT share price targets range from $12.00 to $20.00. On average, they expect the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 117.7% from the stock's current price.
View analysts price targets for ALT
or view top-rated stocks among Wall Street analysts.

How have ALT shares performed in 2024?

Altimmune's stock was trading at $11.25 at the beginning of 2024. Since then, ALT shares have decreased by 38.8% and is now trading at $6.89.
View the best growth stocks for 2024 here
.

When is Altimmune's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ALT earnings forecast
.

How were Altimmune's earnings last quarter?

Altimmune, Inc. (NASDAQ:ALT) posted its quarterly earnings results on Monday, November, 8th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.45. The business had revenue of $0.16 million for the quarter, compared to analysts' expectations of $0.11 million. Altimmune had a negative trailing twelve-month return on equity of 44.77% and a negative net margin of 20,780.75%. During the same period last year, the business earned ($0.54) EPS.

When did Altimmune's stock split?

Shares of Altimmune reverse split on the morning of Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Altimmune own?
Who are Altimmune's major shareholders?

Altimmune's stock is owned by a variety of retail and institutional investors. Top institutional investors include IMC Chicago LLC (0.00%) and EWG Elevate Inc. (0.01%). Insiders that own company stock include David Drutz, Diane Jorkasky, M Scot Roberts, Matthew Scott Harris, Vipin K Garg and Wayne Pisano.
View institutional ownership trends
.

How do I buy shares of Altimmune?

Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners